How to Build a Pharmacovigilance Platform, Adverse Event Reporting, Signal Detection, and EMA/FDA Submission 2026

Every pharmaceutical product on the market has a post-approval safety obligation.

Drug companies must collect, process, and report adverse events, unexpected or harmful reactions to their products, to regulatory authorities on defined timelines: 7 calendar days for fatal or life-threatening unexpected adverse events, 15 calendar days for other serious unexpected events, and periodic aggregate reports (PSUR/PBRER) every 6 to 12 months for all marketed products.

Missing these reporting timelines is not an operational failure. It is a regulatory violation that triggers warning letters, consent decrees, and in extreme cases, market withdrawal of the product.

A pharmacovigilance software development that manages the full adverse event lifecycle, from intake through medical review through regulatory submission, is not optional for a pharmaceutical company. It is the infrastructure for their post-market safety obligation.

The global pharmacovigilance market is projected to reach $12.8 billion by 2030 at a CAGR of 12.4%. The buyers are pharmaceutical companies of all sizes, CROs (Contract Research Organisations) providing PV services, biotechnology companies, and medical device manufacturers.

EngineerBabu built Somnoware, the IoT medical monitoring platform acquired by ResMed, and healthcare platforms for Apollo Hospitals. We understand FDA-regulated healthcare engineering. CMMI Level 5. Google AI Accelerator 2024 Top 20. Contact: mayank@engineerbabu.com

What a Pharmacovigilance Platform Must Handle

Module 1 – Adverse Event Intake

The intake sources:

The intake form, minimum dataset:

An Individual Case Safety Report (ICSR) requires a minimum of four valid data elements to be a reportable adverse event:

1. An identifiable patient (not necessarily named, “64-year-old female” is sufficient)
2. An identifiable reporter (healthcare professional, patient, lawyer, relative)
3. A suspect drug (product name, dose if available)
4. At least one adverse event (the reaction reported)

The intake system flags incomplete cases for follow-up and routes complete cases to medical coding and review.

Web intake form:

A patient-facing or HCP-facing web app form captures adverse event reports directly. The form is available in multiple languages, captures all required MedDRA-codeable elements in a structured way, and routes submitted reports automatically to the case processing queue.

Module 2 – ICSR Processing and MedDRA Coding

The ICSR lifecycle:

MedDRA coding:

MedDRA (Medical Dictionary for Regulatory Activities) is the international standardised terminology used to code adverse events, indications, and medical history in regulatory submissions.

The platform integrates with the MedDRA browser, allowing coders to search the hierarchy (System Organ Class → High-Level Group Term → High-Level Term → Preferred Term → Lowest Level Term) and assign the appropriate codes.

The narrative writing module:

Every ICSR requires a case narrative, a concise medical summary describing the patient, the adverse event, the suspect drug, the clinical course, and the outcome.

The platform provides a narrative template that populates automatically from the case data, the coder reviews and edits the AI-generated draft rather than writing from scratch. For straightforward cases, this reduces narrative writing time from 30 minutes to 5 minutes.

Module 3 – Signal Detection

What is a safety signal:

A safety signal is information suggesting a new, previously unrecognised causal association between a drug and an adverse event, or a known association that has changed in terms of frequency, severity, or affected population. Signals emerge from accumulating ICSRs over time.

Statistical signal detection methods:

The signal detection workflow:

The platform runs disproportionality analysis on the accumulated ICSR database, calculating PRR and ROR for every drug-event combination with at least 3 cases. Combinations exceeding the threshold (typically PRR > 2 and χ² > 4) are flagged as potential signals for pharmacovigilance physician review.

The signal evaluation then determines whether the detected disproportionality represents a genuine safety concern or a statistical artefact, considering confounders, reporting bias, disease background rate, and biologic plausibility.

Module 4 – Regulatory Reporting

The E2B(R3) format:

Individual case safety reports are submitted to regulatory authorities in E2B(R3) XML format, the ICH standard that allows electronic transmission of structured ICSR data.

The platform generates E2B(R3) XML from the case record, mapping every ICSR field to the correct E2B element, and validates the output against the ICH E2B(R3) validation criteria before submission.

Regulatory gateway connections:

The submission tracking dashboard:

Every submission has a status, pending, submitted, acknowledged, accepted, rejected. The platform tracks every submission with its deadline, current status, and any acknowledgement or rejection from the authority. Rejected submissions are flagged immediately with the rejection reason for resubmission.

Module 5 – PSUR and Aggregate Report Generation

The Periodic Safety Update Report (PSUR/PBRER):

A PSUR is a comprehensive safety report on a marketed product, covering all adverse events received during the reporting period, signal detection results, cumulative safety data, and the company’s benefit-risk assessment.

PSURs are submitted to EMA, FDA, and other authorities at defined intervals (annually for most products, more frequently for newer or higher-risk products).

The PSUR generation engine:

The platform generates the PSUR structure automatically, pulling:

All ICSRs received in the reporting period (count by seriousness, expectedness, outcome). Exposure data (number of patients treated).

Disproportionality analysis results from the signal detection module. Comparison against the Reference Safety Information (RSI), the known safety profile against which events are assessed as expected or unexpected.

The medical writer completes the benefit-risk evaluation narrative section, which requires clinical judgment that the platform cannot generate automatically. The rest of the PSUR is pre-populated from operational data.

Build Cost: Pharmacovigilance Software Development

EngineerBabu built Somnoware (acquired by ResMed) and healthcare platforms for Apollo Hospitals. FDA-regulated healthcare engineering experience. CMMI Level 5. Contact: mayank@engineerbabu.com

FAQs about Pharmacovigilance Software Development

• What are the adverse event reporting timelines that pharmaceutical companies must comply with?

Regulatory reporting timelines for adverse events are defined by ICH E2A guidelines and implemented in regional regulations. For serious, unexpected adverse events, reactions not mentioned in the product’s current labelling and meeting seriousness criteria (death, life-threatening, hospitalisation, disability, congenital anomaly, or medically significant), the timelines are: 7 calendar days from awareness for fatal or immediately life-threatening cases, 15 calendar days for other serious unexpected cases. For serious expected adverse events (listed in the product labelling), reporting timelines vary by region, some authorities require expedited reporting, others include them only in periodic reports. Non-serious adverse events are included in Periodic Safety Update Reports (PSURs). Missing these timelines triggers regulatory action, FDA inspections, EMA notices, and in severe cases, voluntary or mandatory market withdrawal of the product.

• What is MedDRA and why is it mandatory for adverse event reporting?

MedDRA (Medical Dictionary for Regulatory Activities) is the international standardised medical terminology developed by ICH for regulatory communication and evaluation of data pertaining to medicinal products for human use. It provides a hierarchical structure, from System Organ Class (the broadest level, e.g., Cardiac disorders) down to Lowest Level Terms (the most specific description of the adverse event), with approximately 70,000 lowest-level terms mapped to approximately 24,000 preferred terms. MedDRA coding is mandatory for ICSR submissions to EMA (EudraVigilance), FDA (FAERS), WHO (VigiBase), and all ICH member regulatory authorities because it standardises the description of adverse events, enabling regulatory authorities to detect safety signals by analysing aggregate data across all ICSRs submitted for a product. Without standardised MedDRA coding, a signal of “liver failure” reported as “hepatic necrosis,” “acute liver injury,” and “fulminant hepatitis” in different ICSRs would not be identifiable as a single safety concern.

• What is a safety signal in pharmacovigilance and how does disproportionality analysis detect it?

A safety signal is a finding suggesting a new or changed causal association between a drug and an adverse event that warrants further evaluation. Disproportionality analysis detects signals by comparing the reporting rate of a specific drug-event combination in the adverse event database against what would be expected if the drug had no association with the event. The Proportional Reporting Ratio (PRR) calculates this as: (reports of event for this drug / all reports for this drug) divided by (reports of event for all other drugs / all reports for all other drugs). A PRR significantly greater than 1, combined with a minimum number of cases (typically 3) and statistical significance, indicates that the drug-event combination is being reported at a higher rate than expected by chance. This statistical signal then triggers a pharmacovigilance physician’s clinical evaluation to determine whether the disproportionality represents a genuine causal safety concern or a statistical artefact from reporting bias, confounding, or the underlying disease.